| Style | Citing Format | 
|---|---|
| MLA | Vahabzadeh A, et al.. "Impact of Corporate Reputation on Brand Segmentation Strategy: An Empirical Study From Iranian Pharmaceutical Companies." Iranian Journal of Pharmaceutical Sciences, vol. 13, no. 1, 2017, pp. 87-104. | 
| APA | Vahabzadeh A, Vatanpour H, Dinarvand R, Rajabzadeh A, Salamzadeh J, Mohammadzadeh M (2017). Impact of Corporate Reputation on Brand Segmentation Strategy: An Empirical Study From Iranian Pharmaceutical Companies. Iranian Journal of Pharmaceutical Sciences, 13(1), 87-104. | 
| Chicago | Vahabzadeh A, Vatanpour H, Dinarvand R, Rajabzadeh A, Salamzadeh J, Mohammadzadeh M. "Impact of Corporate Reputation on Brand Segmentation Strategy: An Empirical Study From Iranian Pharmaceutical Companies." Iranian Journal of Pharmaceutical Sciences 13, no. 1 (2017): 87-104. | 
| Harvard | Vahabzadeh A et al. (2017) 'Impact of Corporate Reputation on Brand Segmentation Strategy: An Empirical Study From Iranian Pharmaceutical Companies', Iranian Journal of Pharmaceutical Sciences, 13(1), pp. 87-104. | 
| Vancouver | Vahabzadeh A, Vatanpour H, Dinarvand R, Rajabzadeh A, Salamzadeh J, Mohammadzadeh M. Impact of Corporate Reputation on Brand Segmentation Strategy: An Empirical Study From Iranian Pharmaceutical Companies. Iranian Journal of Pharmaceutical Sciences. 2017;13(1):87-104. | 
| BibTex | @article{ author = {Vahabzadeh A and Vatanpour H and Dinarvand R and Rajabzadeh A and Salamzadeh J and Mohammadzadeh M}, title = {Impact of Corporate Reputation on Brand Segmentation Strategy: An Empirical Study From Iranian Pharmaceutical Companies}, journal = {Iranian Journal of Pharmaceutical Sciences}, volume = {13}, number = {1}, pages = {87-104}, year = {2017} } | 
| RIS | TY  - JOUR AU - Vahabzadeh A AU - Vatanpour H AU - Dinarvand R AU - Rajabzadeh A AU - Salamzadeh J AU - Mohammadzadeh M TI - Impact of Corporate Reputation on Brand Segmentation Strategy: An Empirical Study From Iranian Pharmaceutical Companies JO - Iranian Journal of Pharmaceutical Sciences VL - 13 IS - 1 SP - 87 EP - 104 PY - 2017 ER - |